These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25363547)

  • 21. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.
    Xu J; Rajaratnam R
    Cardiovasc Diabetol; 2017 Feb; 16(1):18. PubMed ID: 28148253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Incretins have changed and continue to change treatment strategy for type 2 diabetes].
    Kvapil M
    Vnitr Lek; 2011 Nov; 57(11):916-8. PubMed ID: 22165696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know.
    Forsmark CE
    Pancreatology; 2016; 16(1):10-3. PubMed ID: 26795258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.
    Daniels MA; Kan C; Willmes DM; Ismail K; Pistrosch F; Hopkins D; Mingrone G; Bornstein SR; Birkenfeld AL
    Pharmacogenomics J; 2016 Oct; 16(5):399-410. PubMed ID: 27432533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving therapeutic options for type 2 diabetes mellitus: an overview.
    Guthrie RM
    Postgrad Med; 2012 Nov; 124(6):82-9. PubMed ID: 23322141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics of drug response in type 2 diabetes.
    Tkáč I
    Curr Diab Rep; 2015 Jul; 15(7):43. PubMed ID: 25975599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes.
    Salvo F; Faillie JL
    Therapie; 2019 Apr; 74(2):255-260. PubMed ID: 30470475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidiabetes medication initiation trends in US adults with cirrhosis and type 2 diabetes: A nationwide study.
    Simon TG; Wexler DJ; Schneeweiss S; Patorno E
    Diabetes Obes Metab; 2023 Jul; 25(7):2028-2033. PubMed ID: 36938914
    [No Abstract]   [Full Text] [Related]  

  • 30. Assumptions made when preparing drug exposure data for analysis have an impact on results: An unreported step in pharmacoepidemiology studies.
    Pye SR; Sheppard T; Joseph RM; Lunt M; Girard N; Haas JS; Bates DW; Buckeridge DL; van Staa TP; Tamblyn R; Dixon WG
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):781-788. PubMed ID: 29667263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on the comparative effectiveness and safety of medications for type 2 diabetes.
    Goldstein MR; Mascitelli L
    Ann Intern Med; 2011 Oct; 155(8):562-3; author reply 563. PubMed ID: 22007052
    [No Abstract]   [Full Text] [Related]  

  • 32. With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs.
    Turner JR; Caveney E; Gillespie BS; Karnad DR; Kothari S; Metz A; Keller LH
    Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):75-76. PubMed ID: 28122792
    [No Abstract]   [Full Text] [Related]  

  • 33. Type 2 Diabetes - Controlling the Epidemic, Episode 4: Understanding Old and New Therapies for Diabetes.
    Abel ED; Ingelfinger JR; Linhales Barker S; Peek M; Reusch JEB; Rosen CJ
    N Engl J Med; 2023 Oct; 389(16):e31. PubMed ID: 37851873
    [No Abstract]   [Full Text] [Related]  

  • 34. Editorial commentary: New drugs for diabetes: Finally safety and cardiovascular efficacy.
    Connelly KA
    Trends Cardiovasc Med; 2017 Jul; 27(5):376-377. PubMed ID: 28351696
    [No Abstract]   [Full Text] [Related]  

  • 35. [News in Diabetology 2019].
    Jornayvaz FR; Gariani K
    Rev Med Suisse; 2020 Jan; 16(676-7):31-33. PubMed ID: 31961079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial: Pharmacoepidemiology in Diabetes Mellitus and its Complications: Focus on Response to Medications.
    Mohammadi Jouabadi S; Ahluwalia TS; Muka T; Ahmadizar F
    Front Pharmacol; 2022; 13():917977. PubMed ID: 35685644
    [No Abstract]   [Full Text] [Related]  

  • 37. Abstracts of the 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Bordeaux, France, 22-25 August 2004.
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13 Suppl 1():S1-349. PubMed ID: 15295842
    [No Abstract]   [Full Text] [Related]  

  • 38. Latest drug safety alerts from the 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
    Mallarkey G; Mangoni AA
    Ther Adv Drug Saf; 2012 Feb; 3(1):5-11. PubMed ID: 25083221
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.